<DOC>
	<DOCNO>NCT00719706</DOCNO>
	<brief_summary>The primary objective 15-week clinical trial test hypothesis treatment two proven mitochondrial enhancer , acetyl-L-carnitine ( ALCAR ) α-lipoic acid ( ALA ) , significantly great efficacy placebo augmentation treatment bipolar depress patient display incomplete response conventional treatment .</brief_summary>
	<brief_title>The Use Mitochondrial Enhancement Treatment Bipolar Disorder</brief_title>
	<detailed_description>The primary objective propose clinical trial test hypothesis treatment two proven mitochondrial enhancer , acetyl-L-carnitine ( ALCAR ) α-lipoic acid ( ALA ) , significantly great efficacy placebo augmentation treatment bipolar depress patient display incomplete response conventional treatment . We propose test hypothesis perform 15-week placebo-controlled , double-blind , parallel group , flexible-dose study investigate use ALCAR ALA augmentation treatment usual depress bipolar patient . We compare efficacy acetyl-l-carnitine ( ALCAR ) dose 1000-3000mg/day alpha-lipoic acid ( ALA ) dose 600-1800mg/day placebo symptom improvement individual diagnose bipolar disorder type I , current episode depress . Improvement assess use 21-Item Hamilton Depression Rating Scale ( HAM-D ) , Montgomery Asberg Depression Rating Scale ( MADRS ) , Young Mania Rating Scale ( YMRS ) , Clinical Global Impression-Severity Improvement Scales ( CGI-S CGI-I ) . Furthermore , hypothesize improvement depression symptom follow treatment ALCAR ALA associate increase phosphocreatine ( PCr ) , beta-nucleoside triphosphate ( β-NTP ) , intracellular pH anterior cingulate cortex ( ACC ) week 1 week 12 treatment .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>Male female age 1865 year . Meets DSMIV criterion Bipolar Disorder , type I current episode depress . Current score great equal 18 21Item Hamilton Depression Rating Scale Visits 1 2 . Maintained stable treatment regimen change medication dosage least two week prior study entry . Unwilling unable provide inform consent Score great equal 12 Young Mania Rating Scale Visit 1 2 . Current suicidal homicidal ideation . Active psychotic symptom . Lifetime history schizophrenia obsessivecompulsive disorder . DSMIV diagnosis alcohol substance dependence 3 month prior screen . Clinically significant medical condition would interfere study participation . History hypersensitivity ACLCAR ALA . Pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Bipolar disorder</keyword>
	<keyword>Bipolar depression</keyword>
	<keyword>Natural substance</keyword>
	<keyword>Depression</keyword>
</DOC>